Baseline characteristics and subject disposition of subjects with onset of nausea/vomiting from baseline to week 12 and at any time from baseline to end of treatment (yes/no) in the SUSTAIN 3, 7 and 10 trials
| Treatment | Semaglutide 0.5 mg (SUSTAIN 7) | Semaglutide 1.0 mg (pooled) | Exenatide ER 2.0 mg (SUSTAIN 3) | Dulaglutide 0.75 mg (SUSTAIN 7) | Dulaglutide 1.5 mg (SUSTAIN 7) | Liraglutide 1.2 mg (SUSTAIN 10) | ||||||
| N (total) | 301 | 994 | 405 | 299 | 299 | 287 | ||||||
| Nausea/vomiting Yes/No | Y | N | Y | N | Y | N | Y | N | Y | N | Y | N |
| Baseline to week 12 | ||||||||||||
| N | 71 | 230 | 213 | 781 | 50 | 355 | 37 | 262 | 63 | 236 | 54 | 233 |
| Race, n (%) | ||||||||||||
| Asian | 15 (21.1) | 35 (15.2) | 13 (6.1) | 38 (4.9) | 1 (2.0) | 5 (1.4) | 7 (18.9) | 41 (15.6) | 11 (17.5) | 44 (18.6) | 0 (0.0) | 3 (1.3) |
| Black or African American | 3 (4.2) | 14 (6.1) | 11 (5.2) | 37 (4.7) | 2 (4.0) | 28 (7.9) | 0 (0.0) | 17 (6.5) | 2 (3.2) | 16 (6.8) | 0 (0.0) | 1 (0.4) |
| White | 53 (74.6) | 180 (78.3) | 179 (84.0) | 669 (85.7) | 44 (88.0) | 294 (82.8) | 30 (81.1) | 202 (77.1) | 48 (76.2) | 172 (72.9) | 49 (90.7) | 219 (94.0) |
| Other | 0 (0.0) | 1 (0.4) | 10 (4.7) | 37 (4.7) | 3 (6.0) | 28 (7.9) | 0 (0.0) | 2 (0.8) | 2 (3.2) | 4 (1.7) | 5 (9.3) | 10 (4.3) |
| Ethnic group, n (%) | ||||||||||||
| Hispanic or Latino | 8 (11.3) | 21 (9.1) | 25 (11.7) | 107 (13.7) | 11 (22.0) | 95 (26.8) | 4 (10.8) | 27 (10.3) | 11 (17.5) | 32 (13.6) | 1 (1.9) | 2 (0.9) |
| Not Hispanic or Latino | 63 (88.7) | 209 (90.9) | 185 (86.9) | 661 (84.6) | 39 (78.0) | 260 (73.2) | 33 (89.2) | 235 (89.7) | 52 (82.5) | 204 (86.4) | 48 (88.9) | 221 (94.8) |
| Other | 0 (0.0) | 0 (0.0) | 3 (1.4) | 13 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 5 (9.3) | 10 (4.3) |
| Baseline HbA1c, % | 8.3 (1.0) | 8.3 (1.0) | 8.2 (0.9) | 8.3 (0.9) | 8.4 (1.1) | 8.3 (0.9) | 8.2 (0.9) | 8.2 (0.9) | 8.2 (0.8) | 8.2 (0.9) | 8.2 (1.0) | 8.3 (1.0) |
| Baseline BMI, kg/m2 | 32.5 (7.2) | 34.0 (7.1) | 33.1 (6.3) | 34.0 (7.0) | 32.7 (6.2) | 33.7 (6.2) | 35.3 (6.5) | 33.4 (6.9) | 32.3 (6.9) | 33.3 (6.5) | 33.0 (7.8) | 33.8 (6.8) |
| Baseline BW, kg | 92.1 (28.4) | 97.7 (22.9) | 92.4 (19.4) | 97.1 (22.0) | 90.2 (16.7) | 96.1 (20.9) | 98.7 (22.9) | 95.2 (23.0) | 89.7 (21.9) | 94.4 (21.7) | 93.3 (25.2) | 98.1 (20.8) |
| Exposure time, years | 0.7 (0.3) | 0.8 (0.2) | 0.7 (0.3) | 0.9 (0.3) | 1.0 (0.4) | 1.0 (0.3) | 0.8 (0.1) | 0.8 (0.1) | 0.7 (0.3) | 0.8 (0.2) | 0.6 (0.2) | 0.6 (0.1) |
| Duration of diabetes, years | 7.4 (5.9) | 7.8 (5.9) | 8.8 (6.5) | 8.7 (5.9) | 9.6 (7.2) | 9.4 (6.6) | 7.0 (5.2) | 7.0 (5.5) | 7.1 (5.4) | 7.8 (5.7) | 8.2 (5.0) | 9.1 (5.8) |
| Onset of rescue, n (%) | 0 (0.0) | 3 (1.3) | 3 (1.4) | 36 (4.6) | 3 (6.0) | 45 (12.7) | 2 (5.4) | 12 (4.6) | 0 (0.0) | 7 (3.0) | 1 (1.9) | 11 (4.7) |
| Discontinued treatment, n (%) | 21 (29.6) | 26 (11.3) | 61 (28.6) | 111 (14.2) | 12 (24.0) | 73 (20.6) | 3 (8.1) | 24 (9.2) | 15 (23.8) | 21 (8.9) | 10 (18.5) | 16 (6.9) |
| Withdrawal from trial, n (%) | 5 (7.0) | 17 (7.4) | 17 (8.0) | 37 (4.7) | 6 (12.0) | 30 (8.5) | 1 (2.7) | 12 (4.6) | 3 (4.8) | 12 (5.1) | 2 (3.7) | 3 (1.3) |
| Lost to follow-up, n (%) | 3 (4.2) | 6 (2.6) | 9 (4.2) | 13 (1.7) | 2 (4.0) | 8 (2.3) | 0 (0.0) | 8 (3.1) | 1 (1.6) | 7 (3.0) | 1 (1.9) | 2 (0.9) |
| At any time from baseline to EOT | ||||||||||||
| N | 76 | 225 | 245 | 749 | 57 | 348 | 48 | 251 | 69 | 230 | 57 | 230 |
| Race, n (%) | ||||||||||||
| Asian | 16 (21.1) | 34 (15.1) | 14 (5.7) | 37 (4.9) | 1 (1.8) | 5 (1.4) | 8 (16.7) | 40 (15.9) | 12 (17.4) | 43 (18.7) | 0 (0.0) | 3 (1.3) |
| Black or African American | 4 (5.3) | 13 (5.8) | 13 (5.3) | 35 (4.7) | 2 (3.5) | 28 (8.0) | 1 (2.1) | 16 (6.4) | 4 (5.8) | 14 (6.1) | 0 (0.0) | 1 (0.4) |
| White | 56 (73.7) | 177 (78.7) | 207 (84.5) | 641 (85.6) | 51 (89.5) | 287 (82.5) | 39 (81.3) | 193 (76.9) | 51 (73.9) | 169 (73.5) | 51 (89.5) | 217 (94.3) |
| Other | 0 (0.0) | 1 (0.4) | 11 (4.5) | 36 (4.8) | 3 (5.3) | 28 (8.0) | 0 (0.0) | 2 (0.8) | 2 (2.9) | 4 (1.7) | 6 (10.5) | 9 (3.9) |
| Ethnic group, n (%) | ||||||||||||
| Hispanic or Latino | 8 (10.5) | 21 (9.3) | 26 (10.6) | 106 (14.2) | 11 (19.3) | 95 (27.3) | 4 (8.3) | 27 (10.8) | 11 (15.9) | 32 (13.9) | 1 (1.8) | 2 (0.9) |
| Not Hispanic or Latino | 68 (89.5) | 204 (90.7) | 216 (88.2) | 630 (84.1) | 46 (80.7) | 253 (72.7) | 44 (91.7) | 224 (89.2) | 58 (84.1) | 198 (86.1) | 50 (87.7) | 219 (95.2) |
| Other | 0 (0.0) | 0 (0.0) | 3 (1.2) | 13 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 6 (10.5) | 9 (3.9) |
| Baseline HbA1c, % | 8.3 (1.0) | 8.3 (1.0) | 8.2 (0.9) | 8.3 (0.9) | 8.4 (1.1) | 8.3 (0.9) | 8.1 (0.9) | 8.2 (0.9) | 8.1 (0.8) | 8.2 (0.9) | 8.2 (1.0) | 8.3 (1.0) |
| Baseline BMI, kg/m2 | 32.9 (7.6) | 33.9 (6.9) | 33.4 (6.7) | 33.9 (6.9) | 33.0 (6.4) | 33.7 (6.2) | 34.6 (6.7) | 33.5 (6.9) | 32.3 (6.8) | 33.3 (6.5) | 33.4 (8.0) | 33.7 (6.7) |
| Baseline BW, kg | 92.8 (28.2) | 97.6 (22.9) | 93.4 (20.4) | 97.0 (21.9) | 91.0 (16.1) | 96.1 (21.0) | 97.3 (24.0) | 95.3 (22.8) | 89.8 (21.3) | 94.5 (21.9) | 94.0 (25.2) | 98.0 (20.7) |
| Exposure time, years | 0.7 (0.3) | 0.8 (0.2) | 0.8 (0.3) | 0.9 (0.3) | 1.0 (0.4) | 1.0 (0.3) | 0.8 (0.1) | 0.8 (0.1) | 0.7 (0.3) | 0.8 (0.2) | 0.6 (0.2) | 0.6 (0.1) |
| Duration of diabetes, years | 7.3 (5.8) | 7.9 (6.0) | 8.9 (6.5) | 8.6 (5.8) | 9.5 (7.1) | 9.4 (6.7) | 7.1 (5.4) | 7.0 (5.5) | 7.4 (5.8) | 7.7 (5.6) | 8.6 (5.2) | 9.0 (5.8) |
| Onset of rescue, n (%) | 0 (0.0) | 3 (1.3) | 3 (1.2) | 36 (4.8) | 3 (5.3) | 45 (12.9) | 2 (4.2) | 12 (4.8) | 0 (0.0) | 7 (3.0) | 1 (1.8) | 11 (4.8) |
| Discontinued treatment, n (%) | 21 (27.6) | 26 (11.6) | 67 (27.3) | 105 (14.0) | 13 (22.8) | 72 (20.7) | 5 (10.4) | 22 (8.8) | 15 (21.7) | 21 (9.1) | 10 (17.5) | 16 (7.0) |
| Withdrawal from trial, n (%) | 5 (6.6) | 17 (7.6) | 19 (7.8) | 35 (4.7) | 6 (10.5) | 30 (8.6) | 2 (4.2) | 11 (4.4) | 3 (4.3) | 12 (5.2) | 2 (3.5) | 3 (1.3) |
| Lost to follow-up, n (%) | 3 (3.9) | 6 (2.7) | 9 (3.7) | 13 (1.7) | 2 (3.5) | 8 (2.3) | 1 (2.1) | 7 (2.8) | 1 (1.4) | 7 (3.0) | 1 (1.8) | 2 (0.9) |
Data are mean (standard deviation) unless otherwise specified. Only subjects with non-missing subgroup information were selected.
AE, adverse event; BMI, body mass index; BW, body weight; EOT, end of treatment; exenatide ER, exenatide extended release; GI, gastrointestinal; HbA1c, glycated hemoglobin.